Apr 17, 2017 · 20m · top-founders
632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of "The Top," host Nathan Latka interviews Chris Gibson, co-founder and CEO of Recursion Pharmaceuticals, exploring how the company leverages artificial intelligence, robotics, and strategic biotech partnerships to disrupt traditional drug discovery. Gibson details Recursion's capital structure, deal economics, and rapid scaling from an academic spinout into an advanced clinical-stage biotech platform.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Nathan holds 51.4% of the talking time here. How this is scored →
speaking balance: gold is Nathan, purple is the guest (3 minute bins)
Chris firmly declines to disclose specific first-year revenue numbers and directly refutes Nathan's premise that their early partnerships were wonky, piecemeal arrangements.
Hardest push from Nathan ▶ 10:49 Dissecting fundraising totals between debt and equityNathan refuses to let the capital raise figures remain vague, questioning whether debt was double-counted in the equity round and calculating the combined total.
Biggest teaching moment ▶ 3:03 Clarifying biological complexity versus bureaucracyWhen Nathan asks whether abandoned drug assets were held up by bureaucracy, Chris explains the biological realities of target-based drug discovery and how in-human biology often diverges from target expectations.
Nathan holds their own ▶ 7:02 Nathan estimates the operational scale of eight-figure contractsNathan synthesizes the variables discussed to accurately estimate that an eight-figure upfront contract represents over a million experiments and a dedicated team of scientists over multiple months.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Nathan as informed peer | Guest teaching | Guest disagreement | Nathan pushing back | Why |
|---|---|---|---|---|---|---|
| Preview of Episode 632 and Recursion Pharmaceuticals | 3 | 4 | 1 | 1 | Nathan introduces the company and asks basic questions about why historical drug candidates stall. Chris gently clarifies that failures are driven by complex human target biology rather than simple bureaucratic delays. | |
| Structuring Multi-Million Dollar Biotech Partnerships and Royalties | 4 | 4 | 2 | 3 | Nathan pushes for concrete financial numbers on pharma partnerships. Chris maintains confidentiality on specific client contracts but educates Nathan on prototype deal terms including upfront payments, milestones, and perpetual royalties. | |
| Scaling Team, Navigating Tech VC Valuation, and Setting 2017 Goals | 3 | 4 | 2 | 3 | Nathan investigates fundraising totals, valuation mechanics, and early revenue. Chris corrects Nathan on debt versus equity figures, explains how tech VCs view platform biology versus traditional single-asset biotech valuation, and deflects giving precise top-line revenue. | |
| Mid-Roll Sponsorships: Clipfolio Analytics and FreshBooks Invoicing | 0 | 0 | 0 | 0 | Mid-roll sponsor advertisement read by the host for Clipfolio and FreshBooks. | |
| The Famous Five Rapid-Fire Questions with Chris Gibson | 2 | 0 | 1 | 2 | Standard rapid-fire questions where Nathan lightly prods Chris for specific numbers on sleep and software tools before wrapping up the interview. |